Elacytarabine – lipid vector technology overcoming drug resistance in acute myeloid leukemia

Bibliography

• Giles F, O'Brien S, Cortes J, Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer, 2005;104(3):547-54
   PubMed Web of Science ®Google Scholar
• Liliemark JO, Plunkett, W, Dixon, DO. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5′-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res, 1985. 45(11 Pt 2):5952-7
   PubMed Web of Science ®Google Scholar
• Abdel-Aziz W, Jiang HY, Hickey RJ, Malkas, LH. Ara-C affects formation of cancer cell DNA synthesome replication intermediates. Cancer Chemother Pharmacol 2000;45(4):312-19
   PubMed Web of Science ®Google Scholar
• Perrino FW, Mekosh HL. Incorporation of cytosine arabinoside monophosphate into DNA at internucleotide linkages by human DNA polymerase alpha. J Biol Chem 1992;267(32):23043-51
   PubMed Web of Science ®Google Scholar
• Estey E, Plunkett W, Dixon D, Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987;1(8):580-3
   PubMed Web of Science ®Google Scholar
• Kufe D, Spriggs, D, Egan, EM, Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood 1984;64(1):54-8
   PubMed Web of Science ®Google Scholar
• Wiley JS, Jones SP, Sawyer WH. Cytosine arabinoside transport by human leukaemic cells. Eur J Cancer Clin Oncol 1983;19(8):1067-74
   PubMedGoogle Scholar
• Rampazzo C, Gazziola C, Ferraro L, Human high-Km 5′-nucleotidase effects of overexpression of the cloned cDNA in cultured human cells. Eur J Biochem 1999;261(3):689-97
   PubMedGoogle Scholar
• Laliberte J, Momparler RL. Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res 1994;54(20):5401-7
   PubMed Web of Science ®Google Scholar
• Coleman CN, Stoller RG, Drake JC, Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Blood 1975;46(5):791-803
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Thomas X, Calvo F, In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 2002;117(4):860-8
   PubMed Web of Science ®Google Scholar
• Rubas W, Supersaxo A, Weder HG, Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int J Cancer 1986;37(1):149-54
   PubMed Web of Science ®Google Scholar
• Peters GJ, Voorn DA, Kuiper CM, Cell specific cytotoxicity and structure-activity relationship of lipophilic 1-B-D-arabinofuranosylcytosine (ara-C) derivatives. Nucleosides Nucleotides 1999;18(4-5):877-8
   PubMedGoogle Scholar
• Kuiper CM, Van der Wilt CL, Noordhuis P, Lipophilic 1-Beta-D-arabinofuranosyl cytosine (ara-C) derivatives: cell specific cytotoxicity and structure-activity relationship (SAR). Proc Am Assoc Cancer Res 1998;39:306-10
   Google Scholar
• Bergman AM, Kuiper CM, Voorn DA, Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 2004;67(3):503-11
   PubMed Web of Science ®Google Scholar
• Clavis Pharma Ltd Web Site. Available from: http://www.clavispharma.com/Technology
   Google Scholar
• Burke A, Swords R, Kelly K, Elacytarabine. Drugs Future 2009;34(12):941-9
   Web of Science ®Google Scholar
• Boleti H, Coe IR, Baldwin SA, Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacology 1997;36(9):1167-79
   PubMed Web of Science ®Google Scholar
• Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine. Cancer Res 1984;44(11):5029-37
   PubMed Web of Science ®Google Scholar
• Gati WP, Paterson AR, Larratt LM, Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood 1997;90(1):346-53
   PubMed Web of Science ®Google Scholar
• Cai J, Damaraju VL, Groulx N, Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res 2008;68(7):2349-57
   PubMed Web of Science ®Google Scholar
• Wiley JS, Taupin J, Jamieson GP, Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest 1985;75(2):632-42
   PubMed Web of Science ®Google Scholar
• Adema A, Smid K, Losekoot N, Fatty acid derivatives of cytarabine and gemcitabine, CP-4055 and CP-4126, show a prolonged cellular retention compared to the parent drug. AACR Meeting Abstracts 2008;2008( 1_Annual_Meeting):5740-5741
   Google Scholar
• Breistol K, Balzarini J, Sandvold ML, Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Res 1999;59(12):2944-9
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Myhren F, Sandvold ML. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br J Haematol 2009;144(2):273-5
   PubMed Web of Science ®Google Scholar
• Jin G, Matsushita H, Asai S, FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. Biochem Biophys Res Commun 2009;390(3):1001-6
   PubMed Web of Science ®Google Scholar
• Clavis Pharma Press Release 2011. Available from: http://www.clavispharma.com/News+%26+Events/2011+Press+releases/844.cms
   Google Scholar
• Bergman AM, Kuiper CM, Myhren F, Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukemia and solid tumor cell lines. Nucleosides Nucleotides Nucleic Acids 2004;23(8-9):1523-6
   PubMed Web of Science ®Google Scholar
• Milano G, Chamorey AL, Thyss A. Clinical pharmacology of nucleoside analogues. Bull Cancer 2002;89:S71-5
   PubMed Web of Science ®Google Scholar
• Adema AD, Laan AC, Myhren F, Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel. Int J Oncol 2010;36(1):285-94
   PubMed Web of Science ®Google Scholar
• Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003;22(56):9063-74
   PubMed Web of Science ®Google Scholar
• Aamdal S, Dueland S, Lind MJ, Favorable phase I clinical results and pharmacokinetic (PK) data with the novel lipid vector technology-cytotoxic agent, CP-4055. AACR Meeting Abstracts 2005;2005(1):936
   Google Scholar
• Aamdal S, Dueland S, Lind MJ, Phase I trial of a nucleoside analog CP-4055 given daily for 5 days every 3 weeks in patients (pts) with advanced solid tumors - preliminary results. ASCO Meeting Abstracts 2004;22(14 Suppl):2049
   Google Scholar
• Delaunoit T, Raymond E, Awada A, A three schedule phase I trial of CP-4055, weekly and q2 weeks in patients with advanced or metastatic solid tumors. ASCO Meeting Abstracts 2006;24(18 Suppl):2067
   Google Scholar
• Dueland S, Aamdal S, Lundgren L, A multicentre, dose finding, phase II study of CP-4055 in combination with sorafenib in patients with metastatic malignant melanoma. ASCO Meeting Abstracts 2008;26(15 Suppl):20029
   Google Scholar
• Raymond E, Dueland SM, Lind J, Pharmacokinetics of a nucleoside analogue CP-4055 in two phase I trials using a daily for 5 days schedule and three intermittent weekly or biweekly schedules. AACR Meeting Abstracts 2005;2005(1):936
   Google Scholar
• Dueland S, Aamdal S, Lind MJ, Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study. Acta Oncol 2009;48(1):137-45
   PubMed Web of Science ®Google Scholar
• Raymond E, Awada A, Culine S, Phase I trial of CP-4055, a novel cytotoxic agent, given according to three intermittent weekly or biweekly schedules in patients with advanced or metastatic solid tumors: preliminary results. AACR Meeting Abstracts 2005;2005(1):110-c-111
   Google Scholar
• Dueland S, Aamdal S, Nyakas M, A multicentre, dose-finding, phase II Study of CP-4055 in combination with sorafenib in patients with metastatic malignant melanoma. In European Society for Medical Oncology; Stockholm, Sweden; 2008
   Google Scholar
• Giles F, O'Brien S, Vey N, A phase I study with CP-4055 in patients with haematologic malignancies [abstract #0036]. EHA 13th Congress Copenhagen; Denmark; 2008
   Google Scholar
• O'Brien S, Rizzieri DA, Vey N, A phase I/II study with CP-4055 in patients with haematologic malignancies. Blood 2008;112(11):949
   Google Scholar
• O'Brien S, Rizzieri D, Padmanabhan S, A phase I study with CP-4055 and idarubicin in patients with refractory/relapsed AML [abstract #0310]. EHA 14th Congress; Berlin, Germany; 2009
   Google Scholar
• O'Brien S, Rizzieri D, Vey N, A phase II study with CP-4055 as second salvage therapy in patients with AML [abstract #1394]. EHA 14th Congress; Berlin, Germany; 2009
   Google Scholar
• O'Brien S, Rizzieri D, Vey N, A phase II multicentre study with elacytarabine as second salvage therapy in patients with AML. Blood 2009;114(22):1042
   Google Scholar
• Giles FJ, O'Brien S, Rizzieri DA, A phase II study with CP-4055 in patients with second salvage AML. J Clin Oncol 2009;27(15 Suppl):abstract 7047
   Google Scholar
• Rizzieri D, Krug U, Schlenk RF, A phase II study of elacytarabine plus idarubicin as second course remission-induction therapy in patients with acute myeloid leukemia. J Clin Oncol 2011;29(Suppl):abstract TPS207
   Google Scholar
• Rizzieri D, Vey N, Gobbi M, A randomized phase III study of elacytarabine versus limited investigator's choice in patients with refractory acute myeloid leukemia (AML). J Clin Oncol 2011;29(Suppl):abstract TPS206
   Google Scholar
• Adams DJ, Sandvold ML, Myhren F, Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leuk Lymphoma 2008;49(4):786-97
   PubMed Web of Science ®Google Scholar
• Bruheim S, Mlandsmo G, Sandvold ML, Antitumor activity of CP-4055 is enhanced in combination with bevacizumab, cetuximab, and trastuzumab in human NSCLC xenografts. AACR Meeting Abstracts 2007;2007( 3_Molecular_Targets_Meeting):B287
   Google Scholar